NETosis and the Immune System in COVID-19: Mechanisms and Potential Treatments.

COVID-19 NETosis SARS-CoV-2 inflammation therapeutics

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2021
Historique:
received: 11 05 2021
accepted: 22 07 2021
entrez: 23 8 2021
pubmed: 24 8 2021
medline: 24 8 2021
Statut: epublish

Résumé

NETosis is a form of neutrophil death leading to the release of extracellular chromatin and the assembling of proteins, including antiviral proteins, primed by an initial pathogenic stimulus. Under certain specific conditions, neutrophils can exhibit a double-edged activity. This event has been implicated in COVID-19 among other conditions. Neutrophil extracellular traps (NETs) are involved in the pathogenesis of COVID-19 by promoting a pro-inflammatory and a procoagulant state leading to multiorgan failure. This particular form of host defense promoted by neutrophils is closely related to the well-known cytokine storm observed in severe COVID-19 patients. These two elements therefore represent possible targets for treatment of severe SARS-CoV-2 infections.

Identifiants

pubmed: 34421600
doi: 10.3389/fphar.2021.708302
pii: 708302
pmc: PMC8376580
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

708302

Informations de copyright

Copyright © 2021 Gillot, Favresse, Mullier, Lecompte, Dogné and Douxfils.

Déclaration de conflit d'intérêts

Among the authors, JD is CEO and founder of QUALIblood s. a, a contract research organization manufacturing the DP-Filter, is co-inventor of the DP-Filter (patent application number: PCT/ET 2019/052903) and reports personal fees from Daiichi-Sankyo, Mithra Pharmaceuticals, Portola Pharmaceuticals, Roche, Roche Diagnostics and Stago outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Am Geriatr Soc. 2021 Oct;69(10):2752-2758
pubmed: 34235720
Molecules. 2020 May 12;25(10):
pubmed: 32408547
N Engl J Med. 2021 Mar 4;384(9):795-807
pubmed: 33306283
Nat Rev Mol Cell Biol. 2005 Sep;6(9):677-88
pubmed: 16103871
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32353870
Eur Respir J. 2018 Aug 2;52(2):
pubmed: 29946009
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Vascul Pharmacol. 2014 Aug;62(2):63-71
pubmed: 24469066
Arterioscler Thromb Vasc Biol. 2018 Apr;38(4):843-853
pubmed: 29472233
Clin Cancer Res. 2016 Aug 1;22(15):3924-36
pubmed: 26957562
J Clin Invest. 2016 Oct 3;126(10):3783-3798
pubmed: 27599294
Clin Rheumatol. 2020 Jul;39(7):2101-2102
pubmed: 32394215
Mol Med. 2020 Sep 29;26(1):91
pubmed: 32993479
Cell. 2021 Jan 21;184(2):460-475.e21
pubmed: 33278358
Cochrane Database Syst Rev. 2018 Sep 06;9:CD001127
pubmed: 30187450
J Thromb Haemost. 2020 May;18(5):1020-1022
pubmed: 32239799
Eur Respir J. 2018 Apr 26;51(4):
pubmed: 29519921
Sci Immunol. 2018 Aug 24;3(26):
pubmed: 30143555
Plant Physiol. 2009 Oct;151(2):820-9
pubmed: 19700564
J Biol Regul Homeost Agents. 2019 Feb 4;34(1):9-14
pubmed: 32013309
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Cell Biol. 2010 Nov 1;191(3):677-91
pubmed: 20974816
Front Immunol. 2020 Aug 14;11:2072
pubmed: 32922409
JAMA Cardiol. 2020 Jul 1;5(7):751-753
pubmed: 32219362
Science. 2020 May 1;368(6490):473-474
pubmed: 32303591
J Travel Med. 2021 Feb 23;28(2):
pubmed: 33506252
Aging Cell. 2020 Oct;19(10):e13230
pubmed: 33006233
Cell Host Microbe. 2020 Jul 8;28(1):117-123.e1
pubmed: 32411313
Respir Res. 2019 Jul 30;20(1):170
pubmed: 31362723
J Exp Med. 2020 Dec 7;217(12):
pubmed: 32926098
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
J Clin Med. 2020 Sep 11;9(9):
pubmed: 32933031
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9241-9243
pubmed: 32269081
Drugs. 2020 Dec;80(18):1929-1946
pubmed: 33068263
EClinicalMedicine. 2020 Oct;27:100553
pubmed: 33043284
Thromb Haemost. 2012 May;107(5):827-37
pubmed: 22437808
J Transl Med. 2020 May 20;18(1):206
pubmed: 32434518
Ann Rheum Dis. 2021 May;80(5):550-557
pubmed: 33293273
J Neurol Neurosurg Spine. 2016;1(1):
pubmed: 28127589
Science. 2004 Mar 5;303(5663):1532-5
pubmed: 15001782
Front Cell Neurosci. 2017 Jul 24;11:216
pubmed: 28790893
J Clin Invest. 2020 May 1;130(5):2202-2205
pubmed: 32217834
J Infect Dis. 2020 May 11;221(11):1770-1774
pubmed: 32179910
Nature. 2021 Apr;592(7855):616-622
pubmed: 33567448
Cell Mol Immunol. 2019 Jan;16(1):19-27
pubmed: 29572545
Cytokine Growth Factor Rev. 2020 Jun;53:38-42
pubmed: 32360420
Biochem Biophys Res Commun. 2018 Jun 2;500(2):490-496
pubmed: 29673593
Crit Care Res Pract. 2021 Apr 23;2021:8881115
pubmed: 33986957
Front Pharmacol. 2020 Jul 29;11:1169
pubmed: 32848776
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
J Microbiol Immunol Infect. 2020 Jun;53(3):368-370
pubmed: 32205092
J Intensive Care. 2014 Dec 31;2(1):67
pubmed: 25705423
Front Immunol. 2012 Nov 29;3:360
pubmed: 23264775
Allergy. 2020 Jul;75(7):1564-1581
pubmed: 32396996
PLoS One. 2021 Oct 28;16(10):e0259061
pubmed: 34710137
JCI Insight. 2018 Feb 8;3(3):
pubmed: 29415887
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Arthritis Rheumatol. 2020 Dec;72(12):1990-1997
pubmed: 32602262
J Clin Invest. 2012 Jul;122(7):2661-71
pubmed: 22684106
Stem Cell Rev Rep. 2021 Feb;17(1):4-8
pubmed: 32399806
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Front Pharmacol. 2020 Aug 21;11:1307
pubmed: 32973526
Front Immunol. 2020 Jan 31;10:3108
pubmed: 32082301
PLoS One. 2011;6(12):e29318
pubmed: 22195044
Am J Respir Crit Care Med. 2019 Oct 1;200(7):869-880
pubmed: 31162936
Ann Rheum Dis. 2018 Dec;77(12):1825-1833
pubmed: 30131320
J Thromb Haemost. 2018 Feb;16(2):316-329
pubmed: 29156107
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
J Thromb Haemost. 2020 Sep;18(9):2422-2424
pubmed: 32426897
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32302401
Arterioscler Thromb Vasc Biol. 2020 Sep;40(9):2033-2044
pubmed: 32657623
Clin Transl Sci. 2020 Nov;13(6):1096-1102
pubmed: 32881359
N Engl J Med. 2021 Jan 7;384(1):20-30
pubmed: 33332779
Clin Immunol. 2020 May;214:108393
pubmed: 32222466
Am J Respir Crit Care Med. 2019 May 1;199(9):1076-1085
pubmed: 30888839
JAMA. 2021 Aug 10;326(6):499-518
pubmed: 34228774

Auteurs

Constant Gillot (C)

Department of Pharmacy, University of Namur, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, Namur, Belgium.

Julien Favresse (J)

Department of Pharmacy, University of Namur, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, Namur, Belgium.
Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium.

François Mullier (F)

Laboratory Hematology, Université Catholique de Louvain, CHU UCL Namur, Namur Research Institute for Life Sciences (NARILIS), Namur Thrombosis and Haemostasis Centre (NTHC), Yvoir, Belgium.

Thomas Lecompte (T)

Division of Angiology and Haemostasis, University Hospitals of Geneva, Geneva, Switzerland.

Jean-Michel Dogné (JM)

Department of Pharmacy, University of Namur, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, Namur, Belgium.

Jonathan Douxfils (J)

Department of Pharmacy, University of Namur, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, Namur, Belgium.
Qualiblood s.a., Namur, Belgium.

Classifications MeSH